glp-1 prostate cancer May Patients Receiving Agonists Be at Lower Risk of Aggressiveness and Progression? GLP1 Receptor Agonists—Effects beyond Obesity

doi: 10.1371/journal.pone.0134311 104

Third, individual variability in gastric emptying, gastric pH, and gastric motility creates substantial pharmacokinetic variability that is difficult to manage clinically

rely on endogenous production Athletes in cutting phase - Enhanced fat oxidation during training Older adults - Natural carnitine synthesis declines with age Intense training - Higher turnover during exercise Meat eaters with moderate exercise may not need supplementation

Owing to its potent biological availability, replenishing GSH levels following GSH depletion is an important therapeutic target

Running one without the other means one mechanism is always the bottleneck

(3) discovered a small-molecule inhibitor named MLN4924, which selectively inhibits the NEDD8-activating enzyme (NAE) and thereby blocks the initial step of the neddylation pathway